Catalog No.
Product Name
Application
Product Information
Citations
-
immunopotentiator
Inosine pranobex is a potent, broad-spectrum antiviral compound for HIV infection. Inosine pranobex is an immunopotentiator. -
IL-1 inhibitor
IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1). - Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
-
anti-inflammatory agent
Balsalazide is an anti-inflammatory agent for treatment of Inflammatory Bowel Disease. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. -
interleukin-5 receptor antagonist
YM-90709 is an interleukin-5 receptor antagonist. YM-90709 inhibits the binding of IL-5 to its receptor on peripheral human eosinophils and butyric acid-treated eosinophilic HL-60 clone 15 cells, with IC50 values of 1.0 and 0.57 microM, respectively. -
IL-1 inhibitor
AS101, a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme. - Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
-
Smurf1 inhibitor
Smurf1-IN-A01 (A01) is an ubiquitin ligase Smad ubiquitination regulatory factor-1 (Smurf1) inhibitor with a kd of 3.664 nM, which increases BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. -
IL-2 inducer
Nosantine racemate is the racemate of Nosantine. Nosantine is an inducer of IL-2 or enhancer of IL-2 induction by phytohemagglutinin (PHA). -
IL-15 inhibitor
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. - Dexanabinol exhibits not only the antioxidant and neuroprotective activities in brain but also anti-inflammatory activity by inhibiting NF-κB and decreasing cytokines such as TNFα and interleukin-6, which could ensure the integrity of BBB and reduce cell apoptosis and death.
-
IL-2 synthesis inhibitor
NFAT Transcription Factor Regulator-1 is an IL-2 synthesis inhibitor with an IC50 of 182 nM. -
IL receptor agonist
NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone. NO-prednisolone potently stimulates IL-10 production in vivo. -
T cell activator
beta-Interleukin I (163-171), human, a peptide. Interleukins are a group of cytokines (secreted proteins/signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). -
anti-cancer agent
Ginsenoside Rc, isolated from Panax ginseng, may exert various activities including anti-cancer, anti-inflammatory, antiobesity, and anti-diabetic effects. - Gamma-glutamylcysteine (TFA) ((γ-glutamylcysteine (TFA)), an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx).
-
Anti-IL-1β Antibody
Abdakibart is a humanized IgG4 monoclonal antibody that selectively targets IL-1β, a key cytokine involved in the inflammatory response. This reagent is particularly valuable for research applications related to inflammatory diseases, including type 2 diabetes. By inhibiting IL-1β, Abdakibart can help elucidate the pathways involved in inflammation and contribute to the development of novel therapeutic strategies. -
IL-17A Modulator
IL-17A modulator-3 is a selective modulator targeting IL-17A. This compound demonstrates effective inhibition of the IL-17A/A receptor complex with an IC50 value of less than 10 μM. It is suitable for research applications related to inflammation, cancer biology, and autoimmune disorders, providing valuable insights into these critical areas of study. -
Anti-IL-1β Antibody
SSGJ-613 is a fully human monoclonal antibody that targets interleukin-1 beta (IL-1β). This reagent is designed for the investigation of inflammatory conditions, particularly gouty arthritis, by inhibiting the activity of IL-1β, a key mediator in the inflammatory response. Its application extends to research focused on understanding the role of IL-1β in various diseases and therapeutic development. -
IL-17 modulator
IL-17 modulator 6 is a potent inhibitor of Interleukin 17 (IL-17) with a pIC50 of 9.1. This compound effectively modulates IL-17 signaling and is utilized in the study of inflammatory and autoimmune diseases. Researchers may employ IL-17 modulator 6 to explore therapeutic strategies targeting IL-17 pathways. -
IL-2 Fusion Protein
Lecomkafusp alfa is an IL-2 fusion protein designed to enhance immunomodulatory activity. It consists of human IL-2 linked via a protease-cleavable peptide to a humanized single-domain VHH fragment that targets albumin. This compound demonstrates significant antineoplastic properties, making it a valuable tool in cancer immunotherapy research and the exploration of novel therapeutic strategies. -
Anti-IL-17A Antibody
HB-0017 is a humanized IgG1κ monoclonal antibody that specifically targets interleukin-17A (IL-17A). This antibody effectively inhibits IL-6 secretion induced by IL-17A with an IC50 value of 2.09 nM. HB-0017 has demonstrated significant efficacy in reducing ear thickness in a psoriasis-like mouse model induced by Imiquimod, as well as alleviating inflammation in models of IL-17A-induced arthritis and air pouch inflammation. -
Anti-IL-17A Antibody
Velvakiment is a humanized VHH nanobody that specifically targets interleukin-17A (IL-17A). This antibody is valuable for investigating autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, by elucidating the role of IL-17A in inflammatory pathways. Its specificity and affinity facilitate advanced research on therapeutic interventions aimed at modulating IL-17A activity in various disease contexts. -
Anti-IL-17RB Antibody
Ponumkibart is a humanized IgG4κ antibody specifically designed to target the interleukin-17 receptor B (IL-17RB). This antibody serves as a critical tool for investigating the role of IL-17 signaling in various pathologies, including autoimmune diseases and inflammatory conditions. Its application in research includes the study of immune response modulation and the development of therapeutic strategies targeting IL-17 pathways. -
Anti-IL-13 Antibody
Zumilokibart is a humanized IgG1κ antibody that specifically targets interleukin-13 (IL-13). This antibody is designed to inhibit the biological activity of IL-13, a cytokine implicated in various allergic and inflammatory diseases. It is suitable for research applications focused on asthma, allergic rhinitis, and other conditions where IL-13 plays a pivotal role in pathophysiology. -
IL-17 Modulator
IL-17 Modulator 5 is a potent inhibitor targeting interleukin-17 (IL-17) with an IC50 of 1 nM. This compound exhibits significant inhibition of IL-17 associated pathways, playing a critical role in inflammatory responses. It is applicable in research on autoimmune diseases and inflammatory disorders, facilitating investigations into therapeutic avenues for conditions such as psoriasis and rheumatoid arthritis. -
IL-2/IL-2Rα Antagonist
Ro26-4550 TFA is a low micromolar antagonist of the interleukin-2 (IL-2) and IL-2 receptor alpha (IL-2Rα) interaction, exhibiting an IC50 value of 3 μM. This compound serves as a valuable tool for investigating the IL-2 signaling pathway, making it relevant for studies in immunology and cancer research. Its ability to inhibit IL-2 signaling can aid in the understanding of immune responses and the development of therapeutic strategies targeting IL-2 mediated pathways. -
IL-10 Fusion Protein
Vimekofusp is a recombinant IL-10 fusion protein that specifically targets IL10RA and IL10RB receptors. This agent exhibits potent immunomodulatory activity by enhancing anti-inflammatory responses and promoting regulatory T cell functions. It is primarily utilized in research applications focusing on autoimmune diseases, chronic inflammation, and therapeutic strategies aimed at modulating the immune system. -
IL-2 Fusion Protein
Efpixileukin alfa is a fusion protein consisting of a human IL-2 variant connected at the C-terminus to a human immunoglobulin G1 (IgG1) Fc fragment. This immunomodulator enhances T-cell proliferation and activation, making it valuable for therapeutic applications in cancer immunotherapy and autoimmune diseases. Research involving Efpixileukin alfa focuses on its potential to improve immune responses and its role in modulating the tumor microenvironment. -
IL-23 Inhibitor
IL-23 cyclic peptide inhibitor 105 targets the interleukin-23 (IL-23) pathway, serving as a specific inhibitor of this pro-inflammatory cytokine. It exhibits significant potential in modulating inflammatory responses associated with disorders such as inflammatory bowel disease (IBD). This compound is a valuable tool for researchers investigating the role of IL-23 in various inflammatory conditions and developing therapeutic strategies targeting IL-23 signaling. -
IL-17 Modulator
IL-17 Modulator 1 is a small molecule that selectively targets the IL-17 signaling pathway. This compound exhibits high efficacy in modulating IL-17 activity, making it valuable for studying inflammatory diseases. It is particularly relevant in research focusing on psoriasis, ankylosing spondylitis, and psoriatic arthritis, providing insights into mechanisms of disease prevention and treatment. -
IL-17 Inhibitor
IL-17-IN-4 is a potent IL-17 inhibitor with an IC50 of less than 0.1 μM, making it a valuable tool for investigating the role of IL-17 in inflammatory diseases. This compound can facilitate research aimed at understanding the mechanisms of inflammation and the therapeutic potential of IL-17 modulation in conditions such as rheumatoid arthritis and psoriasis. Its high potency enables effective studies of IL-17 signaling pathways in various biological contexts. -
IL-17 Modulator
IL-17 modulator 8 is an orally active modulator targeting interleukin-17 (IL-17). This compound significantly reduces pro-inflammatory cytokines such as IL-6 and IFN-γ, as well as edema. IL-17 modulator 8 is applicable in research focused on arthritis and related inflammatory diseases. -
IL-2/IL-2Rα Binding Antagonis
Ro26-4550 is a potent antagonist of IL-2/IL-2Rα binding, exhibiting an IC50 value of 3 μM. This compound is valuable for investigating the modulation of IL-2 signaling pathways, which play a critical role in T cell proliferation and immune response regulation. Research applications include studying autoimmune diseases, cancer immunotherapy, and potential therapeutic interventions targeting IL-2-mediated effects. -
IL-1β Secretion Inhibitor
K-832 is an orally active inhibitor of IL-1β secretion, targeting the interleukin-1 pathway. This compound demonstrates significant biological activity by reducing inflammatory responses associated with autoimmune disorders. K-832 is applicable in the research of rheumatoid arthritis and other conditions linked to elevated IL-1β levels, making it a valuable tool for studying inflammation and immune response modulation. -
IL-17 Modulator
IL-17 Modulator 9 is an orally active inhibitor targeting the IL-17 pathway. This compound significantly reduces levels of pro-inflammatory cytokines such as IL-6 and IFN-γ while also diminishing edema. It serves as a valuable tool for studying various inflammatory conditions and exploring therapeutic interventions. -
Anti-IL-1βAntibody
Anflekitug is a CHO-expressed human antibody that specifically targets interleukin-1 beta (IL-1β). This monoclonal antibody features a huIgG1 heavy chain and a huκ light chain, exhibiting a predicted molecular weight of 145 kDa. Anflekitug is suitable for applications in inflammatory research, including studies of autoimmune diseases and cytokine signaling pathways. For isotype control experiments, human IgG1 kappa may be used as an appropriate reference. -
IL-17 Modulator
IL-17 modulator 10 is a potent inhibitor of the IL-17 signaling pathway, demonstrating an IC50 of 0.71 μM in HTRF assays that evaluate the binding of IL-17A to IL-17RA. This compound is particularly relevant for research focused on autoimmune and inflammatory diseases, providing valuable insights into therapeutic interventions targeting IL-17-mediated pathways. -
IL-17 Modulator
IL-17 Modulator 2 is an orally active compound that targets the IL-17 pathway. It is effective in significantly reducing levels of pro-inflammatory cytokines, including IL-6 and IFN-γ, while also decreasing edema. This reagent is suited for research applications related to arthritis and other inflammatory conditions. -
IL-1 Inhibitor
E5090 is an orally active inhibitor of IL-1 generation, acting through its conversion in vivo to the active deacetylated form, DA-E5090. This compound exhibits significant anti-inflammatory properties, making it valuable for studies related to inflammation and immune response modulation. E5090 is useful in various immunology research applications, particularly in understanding the role of IL-1 in disease states. -
IL-17A Inhibitor
Acetyl zingerone is an IL-17A inhibitor that exhibits potent anti-inflammatory and antioxidant activities. This compound plays a crucial role in protecting melanocytes from DNA damage by inhibiting matrix metalloproteinases and downregulating IL-17A target gene expression. Acetyl zingerone is valuable for research focused on inflammatory skin conditions and mechanisms of cellular protection. -
IL-1/β-transferase Inhibitor
Pentenocin B is an IL-1/β-transferase inhibitor that selectively targets the interleukin-1 signaling pathway. This compound exhibits weak inhibitory activity against IL-1 and β-transferase, which are crucial in mediating inflammatory responses. Pentenocin B is useful for research applications focused on inflammation and related signaling mechanisms.
